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Objectives: To investigate the levels of testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH),
and prostate-specific antigen (PSA) in prostate cancer patients before and after the switch from degarelix to
leuprolide treatments.
Methods: We enrolled 40 treatment-naïve prostate cancer patients who were treated initially with degarelix and
were later switched to leuprolide. The subjects were divided into three groups depending on when they were
switched to leuprolide: the 3-month group (3m; switched after 84 days, n=10), the 2-month group (2m; 56 days,
n=10), and the 1-month group (1m; 28 days, n=20). Patient symptoms and hormone levels were measured after
switching therapy. The castration level was defined as a serum testosterone level ≤50 ng/dl.
Results: Thirty-nine subjects (97.5%) achieved castration levels of testosterone (11±5.8 ng/dl) 2 weeks after
degarelix was first administered, and the characteristics of these patients were investigated. Testosterone levels
increased and exceeded the castration level in one subject each of the 3m (142 ng/dl), 2m (72 ng/dl), and 1m
groups (63 ng/dl). All subjects achieved the castration level by day 5. In contrast to testosterone levels, the LH and
FSH surge on day 2 was significantly higher in the 1m group than in the other groups. The clinical symptoms were
not exacerbated before or after switching in any patients.
Conclusions: A testosterone surge was observed in 8.3 % of the study patients; however, it was very short-lived
and mild. LH and FSH levels were significantly higher 1 month after administration compared with 2 or 3 months
after degarelix administration.
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Prostate cancer is the most common cancer in males in
Western countries, and its incidence has increased in
Japan [1]. Prostate cancer is dependent on androgens;
therefore, patients are often treated with androgen
deprivation therapy (ADT) [2]. Luteinizing hormone-
releasing hormone (LHRH) agonists are the most preva-
lent form of ADT. The main concern with the use of
LHRH agonists for ADT is the clinical worsening of* Correspondence: miya.yoshi@hotmail.co.jp
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creativecommons.org/publicdomain/zero/1.0/symptoms due to a testosterone surge upon initiation of
LHRH agonist treatment. Therefore, antiandrogens are
often used to reduce the risk of flare up. However, po-
tential adverse drug reactions and the added cost of anti-
androgens must be considered.
The gonadotropin releasing hormone (GnRH) antag-
onist degarelix is a newly discovered agent that blocks
GnRH receptors immediately and testosterone produc-
tion rapidly, preventing a surge. However, degarelix, the
GnRH antagonist currently available in Japan, has thera-
peutic effects that last for only 1 month, and thus, pa-
tients must commute to the hospital once a month tos article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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agonists leuprolide and goselerin are available as 1 and
3 month formulations, respectively. The interval be-
tween hospital visits using 3-month formulations helps
reduce the number of hospital visits, as well as the num-
ber of subcutaneous injections. Therefore, when ADT
treatment is initiated, patients are often switched to a
LHRH agonist empirically after the state of castration is
reached using degarelix, thereby precluding the need for
an antiandrogen. After switching, the patients gain the
benefit of longer intervals between hospital visits.
Garnick et al. firstly reported switching antagonist to
agonists. They demonstrated the endocrinological and
biochemical efficacy of initiating treatment with the
GnRH antagonist abarelix followed by the administra-
tion of LHRH agonists [3]. Zuckerman et al. performed
a prospective evaluation of the testosterone surge when
treatment was switched from 3-month depot injections
of degarelix to leuprolide [4]. They reported that the
fluctuations in serum testosterone were mild and short-
lived, and that there were no symptomatic patients after
switching [4]. Based on these reports, we conducted the
current study to investigate the trends in hormone levels
before and after prostate cancer patients were switched
from degarelix to leuprolide. We also assessed the
changes in hormone levels during different periods of
degarelix administration (1, 2, and 3 months). This is the
first prospective evaluation of hormone levels in the
switch from degarelix to leuprolide in Japanese patients.
Methods
We conducted an investigator-initiated, prospective,
single-arm, open-label trial. The primary objective of
the study was to evaluate the surge in testosterone,
luteinizing hormone (LH), follicle-stimulating hormone
(FSH), and prostate-specific antigen (PSA) and to deter-
mine whether symptoms worsened during the switch
from degarelix to leuprolide. We defined “testosterone
surge” as an increase in testosterone that is an obligate
increase whether an antiandrogen is used or not, and
“clinical flare” as worsening of symptoms due to the in-
crease in testosterone levels. The subjects included 40
treatment-naïve prostate cancer patients (mean age 70.6 ±
7.0 years, range 55−85, mean of body weight 64.2 ± 7.87 kg,
range 49−80, mean of Body Mass Index 23.1 ± 2.65,
range 16.6−27.7, data are presented as mean ± Standard
Deviation, S.D.) who were treated initially with degarelix
hormone therapy and later switched to leuprolide. The
characteristics of patients are shown in Table 1. Because
of concern about the occurrence of testosterone flare,
which worsens pain upon bone metastasis, we selected
only patients who had no such metastasis. 24 patients
(mean age 67.6 years) received radiation therapy with
hormonal therapy. 16 patients (mean of age 75.7) weretreated by continuous androgen deprivation therapy for
their preference. The subjects were divided into three
groups depending on when they were switched to
3.75 mg leuprolide. The 3-month (3 m) group was given
240 mg degarelix via two 120-mg deep subcutaneous
injections, to initiate ADT, at day -84, followed by two
80-mg maintenance doses (n = 10). The 2-month (2 m)
group was treated with 240 mg degarelix at day -56 via
two 120-mg deep subcutaneous injections, to initiate
ADT, followed by a single 80-mg maintenance dose
(n = 10). Finally, patients in the 1-month (1 m) group
were treated with 240 mg degarelix via two 120-mg
deep subcutaneous injections to initiate ADT at day -28,
with no maintenance dose (n = 20). The day on which
the medications were switched was recorded as day 0.
The symptoms were confirmed, and hormone levels
were measured on days 0, 1, 2, 5, 7, and 28. No patient
received any antiandrogen. Serum LH and FSH were mea-
sured using a chemiluminescent immunoassay (CLIA).
PSA was measured using a chemiluminescent enzyme im-
munoassay (CLEIA). Testosterone in all samples was mea-
sured with an electrochemiluminescence Immunoassay
(ECLIA). It has been reported that the correlation coeffi-
cients for automated immunoassays are relatively poor
when testosterone concentrations are low (<4.0 nmol/L)
[5], so we also measured serum testosterone on days 0, 1,
2, 5 and 7 via liquid chromatography-tandem mass spec-
trometry (LC-MS/MS). The castration level was defined
as a serum testosterone level ≤50 ng/dl. This study was
conducted with approval from the Gunma University
Clinical Research Ethics Committee. Friedman and
Wilcoxon Signed-Rank tests and one-factor ANOVA
were used to compare PSA and hormonal parameters
among the groups. Multivariate analyses were per-
formed using a linear regression model, and p < 0.05
was considered indicative of statistical significance. All
statistical analyses were performed using commercially
available statistical software (SPSS ver. 21.0 IBM, Chi-
cago, IL, USA).Results
A total of 40 patients aged 55–85 years (70.6 ± 7.0,
mean ± S.D.) were enrolled in the study between July
and October of 2013. The baseline patient characteristics
are shown in Table 1.Testosterone determined by ECLIA
The mean testosterone level before initiating ADT using
degarelix was 470.4 ± 161.1 (mean ± S.D.) ng/dl. One pa-
tient in the 1 m group was excluded from the analysis
because his testosterone did not reach castration level
(166 ng/dl) before switching to leuprolide. After adminis-
tering a 3.75-mg dose of leuprolide, he reached castration
Table 1 Clinical characteristics of the patients
All patients 3 m group 2 m group 1 m group p-value
n 40 10 10 20
Age 70.6 ± 7.0 73.4 ± 7.9 72.1 ± 6.9 68.5 ± 6.2 0.147
BW (kg) 64.2 ± 7.9 61.7 ± 6.9 62.0 ± 8.9 66.1 ± 6.8 0.289
Height (cm) 166.6 ± 5.1 166.9 ± 3.4 164.5 ± 6.2 165.9 ± 5.3 0.166
BMI 23.1 ± 2.6 22.1 ± 2.3 22.9 ± 2.9 24.0 ± 2.1 0.295
PSA 12.0 ± 9.9 8.91 ± 7.10 17.6 ± 14.9 10.65 ± 6.84 0.177
GS; n (%)
6 5 (12) 2 (20) 3 (15)
7 22 (55) 7 (70) 4 (40) 11 (55)
8 8 (20) 3 (30) 2 (20) 3 (15)
9 5 (13) 2 (20) 3 (15)
TNM classification; n (%)
T1cN0M0 5 (13) 2 (20) 3 (15)
T2N0M0 22 (55) 8 (80) 4 (40) 10 (50)
T3N0M0 13 (33) 2 (20) 4 (40) 7 (35)
D’Amico risk classification; n (%)
low 2 (7) 1 (10) 1 (5)
intermediate 12 (40) 3 (30) 2 (20) 7 (35)
poor 16 (53) 7 (70) 7 (70) 12 (60)
Data are presented as means ± SD unless indicated otherwise
BW body weight; BMI Body Mass Index; PSA prostatic specific antigen; GS Gleason score; SD standard deviation
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reach castration level (mean of testosterone 7.5 ± 5.8 ng/dl,
mean ± S.D.) before switching to leuprolide from degarelix
were included in the analysis. The data are shown in
Table 2. A testosterone surge of up to 50 ng/dl was ob-
served in three cases (7.7 %) (59.0 ng/dl in one patient,
No.30 in the 1 m group, 69.0 ng/dl in one patient, No.18
in the 2 m group, and 161.0 ng/dl in one patient, No.10 in
the 3 m group).Testosterone determined by LC-MS/MS
We measured serum testosterone on days 0, 1, 2, 5, and
7 via LC-MS/MS because it has been reported that the
correlations between the results of automated immuno-
assays are poor when testosterone concentrations are
low (<4.0 nmol/L) [5]. We were not able to evaluate tes-
tosterone levels in three patients on the day of the
switch from degarelix (1 patient in 2 m group, 2 patients
in 1 m group) because no serum remained after ECLIA
assay. We evaluate testosterone by LC-MS/MS in 36 pa-
tients. The data are shown in Table 2. In 36 patients, mean
testosterone level was 8.6 ± 4.4 ng/dl on day of switching
to leuprolide from degarelix as day 0, 24.1 ± 25.3 ng/dl on
day 1, 22.6 ± 20.6 ng/dl on day 2, 8.6 ± 2.7 ng/dl on day 5,
8.0 ± 3.0 ng/dl on day 7 (mean ± S.D.). Similar with the
results found with the ECLIA, after the administrationof leuprolide, a testosterone surge of up to 50 ng/dl was
observed in the same three cases (8.3 %) (63 ng/dl in
one patient, No.30 in the 1 m group, 80 ng/dl in one pa-
tient, No.18 in the 2 m group, and 142 ng/dl in one pa-
tient, No.10 in the 3 m group). These three patients
returned to castration level within 5 days of switching,
and all patients maintained testosterone below the
castration level until the end of the observation period
(Fig. 1). A testosterone surge was observed in 8.3 % of
the study 36 patients by LC-MS/MS. In 33 patients
who had no testosterone surge of up to 50 ng/dl,
mean testosterone level was 7.9 ± 3.0 ng/dl on day 0,
17.9 ± 10.3 ng/dl on day 1, 19.1 ± 13.4 ng/dl on day 2,
8.4 ± 2.6 ng/dl on day 5, 7.6 ± 2.6 ng/dl on day 7
(mean ± S.D.). There was no significant difference in
the width or frequency of the testosterone surge
among the three groups.PSA
PSA was reduced in all groups after the administration
of degarelix (mean PSA ± S.D. before vs. after: 3 m
group, 9.88 ± 6.97 vs. 0.63 ± 0.61 ng/ml; 2 m group, 17.8
± 14.8 vs. 2.05 ± 4.30 ng/ml; 1 m group, 11.8 ± 7.30 vs.
3.91 ± 4.32 ng/ml). There were no significant elevations
of PSA levels in any of the groups after switching to
leuprolide (Table 3).
Table 2 Serum testosterone on each days after switching to lueprolide
Day 0 Day 1 Day 2 Day 5 Day 7
ECLIA Total (n = 39) 7.5 ± 5.8 19.7 ± 27.5 17.4 ± 18.2 7.0 ± 4.8 6.7 ± 4.6
Surge (-)
Total (n = 36) 7.6 ± 6.0 13.5 ± 10.6 14.3 ± 11.2 7.1 ± 4.8 6.8 ± 4.7
3 m group (n = 9) 8.2 ± 6.8 11.9 ± 10.6 11.9 ± 11.4 7.9 ± 5.7 6.9 ± 5.0
2 m group (n = 9) 6.0 ± 5.6 10.6 ± 11.9 9.0 ± 8.0 6.0 ± 5.7 6.3 ± 5.6
1 m group (n = 19) 8.2 ± 5.9 15.7 ± 5.9 18.2 ± 11.5 7.2 ± 4.0 7.1 ± 4.1
Surge (+)
No.10 (3 m) 10.0 161.0 88.0 3.0 3.0
No.18 (2 m) 3.0 63.0 69.0 3.0 3.0
No.30 (1 m) 3.0 59.0 5.0 12.0 9.0
LC-MS/MS Total (n = 36) 8.6 ± 4.4 24.1 ± 25.3 22.6 ± 20.6 8.6 ± 2.7 8.0 ± 3.0
Surge (-)
Total (n = 33) 7.9 ± 3.0 17.9 ± 10.3 19.1 ± 13.4 8.4 ± 2.6 7.6 ± 2.6
3 m group (n = 9) 8.6 ± 3.3 15.7 ± 12.3 15.4 ± 11.5 8.4 ± 3.4 8.0 ± 3.1
2 m group (n = 8) 6.4 ± 2.6 14.9 ± 12.5 11.1 ± 11.1 6.8 ± 2.7 6.6 ± 3.2
1 m group (n = 16) 8.3 ± 2.9 20.8 ± 7.4 24.4 ± 13.7 9.2 ± 1.6 7.9 ± 1.9
Surge (+)
No.10 (3 m) 28.0 142.0 93.0 12.0 16.0
No.18 (2 m) 12.0 72.0 80.0 9.0 12.0
No.30 (1 m) 7.0 63.0 7.0 12.0 9.0
Data are presented as means ± SD unless indicated otherwise
ECLIA electrochemiluminescence Immunoassay; LC-MS/MS liquid chromatography-tandem mass spectrometry; surge (-) means a testosterone surge of down to
50 ng/dl was observed, surge (+) means a testosterone surge of up to 50 ng/dl was observed
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In contrast, there were significant differences in the me-
dian LH surge after switching. The mean of LH surge on
day 2 was 1.97 ± 1.97 mIU/ml in the 3 m group, 1.57 ±
1.58 mIU/ml in the 2 m group, and 6.21 ± 3.73 mIU/ml
in the 1 m group (mean ± S.D.) . LH levels were signifi-
cantly higher in the 1 m group than the other two groups
(vs. 3 m group, p = 0.023; vs. 2 m group, p = 0.009; Fig. 2a).
Similarly, there was also an FSH surge on day 2. The mean
of FSH surge was 5.24 ± 3.81 mIU/ml in the 3 m group,
4.05 ± 1.77 mIU/ml in the 2 m group, and 10.53 ± 6.59
mIU/ml in the 1 m group (mean ± S.D.). The FSH surge
was higher in the 1 m group than in the other two groups
(vs.3 m group, p = 0.019; 2 m group, p = 0.001; Fig. 2b).
Predictive factors of testosterone surge
We performed univariate and multivariate logistic ana-
lyses in order to predict which patients might more
likely to experience a testosterone surge, measured via
LC-MS/MS, during the switch from degarelix to leupro-
lide. The results of multivariate analysis (linear analysis)
are shown in Table 4. The period of degarelix adminis-
tration and LH levels at the time of switching to leupro-
lide were significantly related to a testosterone surge
with the switch to leuprolide. The testosterone surgecould be predicted using the following formula: predicted
testosterone surge (ng/dl) = 100 × { 0.196 + (0.445 ×
serum LH on switching [mIU/ml]) + (−0.091 × period of
administration of degarelix [months]) }. The testosterone
surge decreased with an increasing period of administration
of degarelix. Conversely, the testosterone surge increased
as the LH level upon switching to leuprolide increased.
No patients experienced symptoms associated with a tes-
tosterone surge during the observation period. In addition,
we found no significant changes in PSA level in any pa-
tient after switching to leuprolide.
Discussion
ADT has been a long-term treatment for prostate cancer
patients since it was first reported by Huggins et al. [6].
It is used as the first-line treatment for patients with
metastatic prostate cancer. LHRH agonists are used for
castration, and their effectiveness is equivalent to that of
surgical castration [7]. However, the testosterone surge
that occurs during the early stage of treatment remains
problematic because it might exacerbate the disease state
temporarily [8]. Reports have suggested that patients
with bone metastasis might experience a worsening of
bone pain, and that a worsening of symptoms associated
with spinal cord compression might be observed in
Fig. 1 Serum testosterone levels (LC-MS/MS) of the study patients at various time points. After the administration of leuprolide, a testosterone
surge of up to 50 ng/dl was observed in same three cases (63 ng/dl: No.30 in the 1 m group, 80 ng/dl: No.18 in the 2 m group, and 142 ng/dl:
No.10 in the 3 m group). “surge (-) total (n = 33)” shows mean of serum testosterone in 33 patients who has no testosterone surge of up to
50 ng/dl. Error bar shows S.D
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tients in 9 series found 10.9 % who suffered disease flare
and 15 who died during disease flare. (in Thompson
et al.) [9]. To manage this testosterone surge, oral anti-
androgens such as bicalutamide and flutamide are gener-
ally administered before initiating treatment with LH-
RH agonists [10–12]. However, reports have suggested
that it is not possible to prevent the testosterone surge
completely, even when antiandrogens are used before
LHRH agonists. Klotz et al. reported the efficacy and
safety of degarelix in a phase III study in 2008. A total of
201 patients were treated with 7.5 mg leuprolide per
month, and 23 patients (11 %) received concomitant
bicalutamide for flare protection at the start of treat-
ment. The 144 patients (81 %) without bicalutamide ex-
perienced a testosterone surge (an increase of >15 %
from baseline). Despite of receiving bicalutamide, 17 of
23 (74 %) patients experienced a similar testosterone
surge [13].Table 3 Serum PSA on each days after switching to lueprolide
Day 0 Day 1
total (n = 39) 2.61 ± 3.86 2.47 ± 3.66
3 m group (n = 10) 0.628 ± 0.611 0.614 ± 0.592
2 m group (n = 10) 2.05 ± 4.30 1.94 ± 4.04
1 m group (n = 19) 3.88 ± 4.21 3.66 ± 4.02
Data are presented as means ± SD (ng/ml) unless indicated otherwise
PSA Prostate Specific AntigenGnRH antagonists do not cause a testosterone surge,
and they can produce a state of castration more rapidly
than LHRH agonists. Studies assessing the therapeutic
effects of GnRH antagonists in patients with metastasis
demonstrated that the period prior to PSA re-elevation
was prolonged, and the effects long-term [14]. Two re-
ports described switching prostate cancer patients from
an antagonist to an agonist. First, Garnick et al. demon-
strated the safety and endocrinological and biochemical
efficacy of initiating treatment with the LH-RH antagon-
ist abarelix followed by the administration of agonists. A
total of 176 patients received ADT with abarelix for
12 weeks, followed by maintenance ADT with a LH-RH
agonist for 8 weeks. It was reported that 93.8 % of patients
attained castration levels of testosterone (<50 mg/dL) after
initiation of abarelix therapy, and that 91 % of patients
remained at such levels after switching to the agonist. In
addition, the mean testosterone levels of the 176 patients
increased by a mean of 19.6 ng/dl (range, 17.7–37.3 ng/dl)Day 2 Day 5 Day 7
2.43 ± 3.75 1.95 ± 2.43 1.92 ± 2.63
0.631 ± 0.625 0.665 ± 0.621 0.655 ± 0.614
2.05 ± 4.31 2.01 ± 3.99 2.13 ± 4.44
3.52 ± 4.10 2.58 ± 1.71 2.53 ± 1.68
Fig. 2 Mean serum LH and FSH surge in the study patients on day 2. a LH levels were significantly higher in the 1 m group than the other two
groups (*; vs. 3 m group, p = 0.023; vs. 2 m group, p = 0.009; Fig. 2a). b The FSH surge was higher in the 1 m group than in the other two groups
(**; vs.3 m group, p = 0.019; 2 m group, p = 0.001; Fig. 2b). Error bar shows S.D
Table 4 Multivariate analysis for predicting testosterone surge (LC-MS/MS)
Univariate analysis Multivariate analysis (linear analysis)
Variables P value Partial regression coefficient 95% CI lower 95% CI upper P value
Age 0.140




Serum T (before ADT) 0.688
Serum T (after switching therapy) 0.948
Serum LH (before ADT) 0.820
Serum LH (after switching therapy) <0.001 0.445 0.339 0.551 <0.001
Serum FSH (before therapy) 0.747
Serum FSH (after switching therapy) 0.406
GS Gleason score; ADT androgen deprivation therapy; T testosterone; LH luteinizing hormone; FSH follicle-stimulating hormone; CI confidence interval
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occurred as a result of switching therapy [3]. A subsequent
study by Zuckerman et al. performed a prospective evalu-
ation of testosterone fluctuations associated with the switch
from degarelix to leuprolide in 45 patients. They observed a
rise in mean testosterone from a nadir of 16.5 ng/dl to a
peak of 25.8 ng/dl (p = 0.0005). Four patients (8.9 %) experi-
enced a testosterone surge with a mean peak serum level of
80.7 ng/dl the day of switching; all four patients returned to
castrate levels within 7 days of switching, and no patients
experienced a symptomatic flare [4].
In the current study, we observed a testosterone surge
of 50 ng/dl or greater in one of 10 subjects who received
degarelix every 3 months (patient no. 10), one of 9 sub-
jects who received degarelix every 2 months (patient no.
18), and one of 17 who received degarelix once a month
(patient no. 30). All patients who experienced a testos-
terone surge returned to the castrate state within 3 days
of switching. No significant differences were observed
regarding the severity or frequency of the testosterone
surge among groups. In addition, no patient experienced
symptomatic exacerbations related to the testosterone
surge because no patient had bone metastasis, and no
elevation in PSA level was noted after switching. There-
fore, although surges were observed at the time of
switching, none reached a level that was considered clinically
problematic. Therefore, it seems that transition of therapy
from degarelix to leuprolide is safe after any duration of
treatment with degarelix (3 months, 2 months, or 1 month).
Interesting results were observed regarding the LH
and FSH dynamics during degarelix administration and
at the time of switching. The surges of LH and FSH were
larger in the 1-month group, which suggests that the
suppression of the pituitary gland was weaker. In
addition, the surge at the time of agonist use was not
stronger in individuals receiving the 240 mg dose of
degarelix 2 or 3 months before the switch to leuprolide
compared to those who received the 240 mg dose
1 month before the switch. Although there were differ-
ences in the LH and FSH surges according to the period
of degarelix administration, there were no significant dif-
ferences in the mean of testosterone surge among
groups, which might have been caused by a suppression
of the testicular response. When we focused on individ-
ual cases we found that a small testosterone surge was
observed in a few patients and that it did not induce a
change in PSA levels. The testosterone surges observed
in the present study were mainly affected by LH levels
on switching to leuprolide and period of administration
of degarelix. Although it is possible that a testosterone
surge might still occur because of decreased serum concen-
trations of the antagonist immediately after switching from
a LHRH agonist, Zuckerman et al. reported that no testos-
terone surge was evident immediately after switching,according to testosterone level measurements in samples
taken 1, 2, 3, and 4 weeks after switching to the agonist [4].
In the current study, treatment was initiated using a
GnRH antagonist, and subjects were then switched to an
LHRH agonist. Although testosterone surges were ob-
served in some subjects, they were small and none
reached a level that was clinically problematic; this sug-
gests that this treatment is safe. However, the current
study did not include subjects with bone metastasis. In
addition, patients with multiple metastatic lesions at the
time of the initial examination and malignant tumors
with a high Gleason score might benefit more from the
use of an antagonist than an agonist during long-term
ADT therapy. In Japan, the combined androgen block-
ade using LHRH agonist and antiandrogens is popular in
both non-metastatic and metastatic stages of prostate
cancer [15, 16]. Based on the present findings, switching
from degarelix to leuprolide appears to be a reasonable
therapeutic option in prostate cancer patients without
metastatic extension, since it does not result in a disease
flare-up, and that it does not require an additional treat-
ment with anti-androgens.
Conclusion
GnRH antagonists such as degarelix can rapidly produce
a state of castration. The mean level of testosterone in
patients of our study before initiating ADT using degare-
lix was 470.4 ± 161.1 ng/dL, compared to 8.5 ± 4.4 ng/dL
before switching to leuprolide. A testosterone surge was
observed in 8.3 % of the study patients; however, it was
very short-lived and mild. There was no significant
change in PSA level in any group after switching to leu-
prolide. No patients experienced symptoms associated
with a testosterone surge during the observation period.
In contrast, we found significant differences in the me-
dian LH and FSH surges after switching. LH and FSH
surge levels were significantly higher 1 month after
degarelix administration compared to 2 or 3 months
thereafter. Based on the present findings, switching from
degarelix to leuprolide appears to be a reasonable thera-
peutic option in prostate cancer patients without meta-
static extension, since it does not result in a disease
flare-up, and that it does not require an additional treat-
ment with anti-androgens.
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